


SMA COMMUNITY UPDATE FROM BIOGEN

As part of our commitment to keeping you informed about SPINRAZA® (nusinersen) and our support for the SMA community, we are thrilled to share updates from the Cure SMA 2026 Annual SMA Conference.

Meeting and hearing from so many families affected by SMA was a privilege and the perfect opportunity to celebrate a major milestone: the FDA approval of the High Dose Regimen of SPINRAZA.

We share this achievement with all of you. Your leadership, advocacy and willingness to show up have expanded research, supported clinical trials and created new hope. Now, we are stepping into an exciting new chapter together.

This moment is about more than celebrating how far we have come; it is about embracing what comes next for individuals impacted by SMA. This is what true impact looks like—and we are just getting started.



Ready for More campaign

Ready for More

To coincide with the conference, we launched **Ready for More**, a new campaign that highlights the High Dose Regimen of SPINRAZA with an updated visual style designed to spotlight individuals with SMA.

We introduced the campaign with an immersive red carpet-style premiere experience at our conference booth.

To explore the campaign and find resources on High Dose SPINRAZA, visit SPINRAZA.com.




Scan here for new resources
available on SPINRAZA.com


New Resources



Getting Started Guide



Doctor Discussion Guide



Dosing Planner

WHAT IS SPINRAZA?

SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Please see additional Important Safety Information on last page and full Prescribing Information [here](https://SPINRAZA.com).

SMA COMMUNITY UPDATE FROM BIOGEN (cont.)

Memorable Conference Experiences

Additional features and activities we offered attendees this year included:

Chapter & Leadership Meeting & Reception

We participated in the Cure SMA Chapter & Leadership Meeting and hosted a reception featuring a roundtable on Biogen's preparation for the High Dose SPINRAZA launch. We are humbled by the strong interest and excitement across the SMA community about the recently approved High Dose Regimen, and we're bringing valuable feedback and insights back to our team to help inform our ongoing efforts.



Symposium

Our sponsored symposium brought together Dr. Natalie Gillson and Kurt, an adult living with SMA, who shared their early experiences with High Dose SPINRAZA.

Family-Friendly Poster Session

We shared results from the Phase 2/3 DEVOTE study that evaluated the High Dose Regimen of SPINRAZA in an accessible way for families and supporters to learn about our research findings.



WHAT IS SPINRAZA?

SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Increased risk of kidney damage, including potentially fatal acute inflammation of the kidney, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk.

The most common side effects of SPINRAZA in the Low Dose Regimen in infantile and later-onset SMA include lower respiratory infection, constipation, fever, headache, vomiting, back pain, and post-lumbar puncture syndrome.

The most common side effects of SPINRAZA in the High Dose Regimen in infantile-onset SMA include pneumonia, COVID-19, pneumonia aspiration, and malnutrition. COVID-19 was not discovered at the time of the studies for the Low Dose Regimen.

These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at **1-800-FDA-1088**.

Before taking SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant.

Please see full [Prescribing Information](#).

This information is not intended to replace discussions with your healthcare provider.